Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.

Codiak BioSciences, a US-based exosome therapeutics developer, has filed to raise up to $86.3m in an initial public offering. Founded in 2015, Codiak is developing exosome therapeutics to treat a range of conditions, including cancer, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders and rare diseases. The company’s therapeutics are created by engineering exosomes, extracellular…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.